Literature DB >> 19167976

Improved hepatocyte function of future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting.

Kun-Ju Lin1, Chien-Hung Liao, Ing-Tsung Hsiao, Tzu-Chen Yen, Tse-Ching Chen, Yi-Yin Jan, Miin-Fu Chen, Ta-Sen Yeh.   

Abstract

BACKGROUND: Preoperative portal vein embolization is increasingly employed for those with hepatocellular carcinoma and cirrhosis to gain a volume-shifting effect. However, the alterations of histologic architecture and hepatocyte function of future liver remnant (FLR) remain unexplored.
METHODS: Portal vein ligation (PVL) was performed in cirrhotic and noncirrhotic rats. Regeneration indices that include the DNA synthesis index, restituted liver mass, and the redistributed volume ratio were measured. The indocyanine green 15' retention test (ICG-R15), histologic changes, total Knodell score, and activated hepatic stellate cells (HSCs) were measured before and after PVL. Tc-99m sulfur-colloid liver single photon emission computed tomography (SPECT) and diisopropyl iminoacetic acid (DISIDA) SPECT were conducted.
RESULTS: The redistributed volume ratio of cirrhotic rats was less than noncirrhotic rats (63% vs 80%, P < .01). The ICG-R15 of cirrhotic rats at day 7 after PVL was improved compared with baseline (6.0 +/- 4.1% vs 15.8 +/- 4.6%, P < .01). The total Knodell score and activated HSCs of FLR in cirrhotic rats both were decreased compared with those of baseline. The redistributed volume ratio of noncirrhotic and cirrhotic rats based on 99mTc sulfur-colloid SPECT were 79% and 64%, respectively. The clearance T(1/2) of FLR in cirrhotic rats based on DISIDA SPECT was decreased compared with baseline (5.2 +/- 1.9 min vs 8.6 +/- 3.1 min).
CONCLUSION: The regenerated functional liver mass of cirrhotic rats after PVL is less than noncirrhotic rats, whereas the hepatocyte function of FLR in cirrhotic rats is improved relevant to tissue remodeling.

Entities:  

Mesh:

Year:  2009        PMID: 19167976     DOI: 10.1016/j.surg.2008.10.006

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Comparison of percutaneous transhepatic portal vein embolization and unilateral portal vein ligation.

Authors:  Hiroya Iida; Tsukasa Aihara; Shinichi Ikuta; Hidenori Yoshie; Naoki Yamanaka
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

2.  Portal branch ligation does not counteract the inhibiting effect of temsirolimus on extrahepatic colorectal metastatic growth.

Authors:  Sebastian Senger; Jens Sperling; Barbara Oberkircher; Martin K Schilling; Otto Kollmar; Michael D Menger; Christian Ziemann
Journal:  Clin Exp Metastasis       Date:  2017-06-19       Impact factor: 5.150

3.  Activation of inactive hepatocytes through histone acetylation: a mechanism for functional compensation after massive loss of hepatocytes.

Authors:  Yujun Shi; Huaiqiang Sun; Ji Bao; Ping Zhou; Jie Zhang; Li Li; Hong Bu
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

4.  Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation.

Authors:  Jens Sperling; Christian Ziemann; Anika Gittler; Anna Benz-Weißer; Michael D Menger; Otto Kollmar
Journal:  Clin Exp Metastasis       Date:  2015-02-19       Impact factor: 5.150

5.  Multiple low doses of erythropoietin delay the proliferation of hepatocytes but promote liver function in a rat model of subtotal hepatectomy.

Authors:  Hua-sheng Peng; Xian-hua Xu; Ru Zhang; Xiao-ying He; Xiao-xiang Wang; Wuan-hua Wang; Ting-yuan Xu; Xing-rong Xiao
Journal:  Surg Today       Date:  2014-04-03       Impact factor: 2.549

6.  Assessment of remnant liver function and volume after selective ligation of portal vein and hepatic artery in a rat model.

Authors:  Thiago Boechat de Abreu; Alexandre de Abreu Ribeiro; Lívia Paola Colchete Provenzano; Joaquim Ribeiro Filho; Alberto Schanaider
Journal:  Acta Cir Bras       Date:  2020-01-10       Impact factor: 1.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.